DEF 14A: Mountain Crest Acquisition Corp. V Seeks Extension to Complete Business Combination with CUBEBIO

Mountain Crest Acquisition Corp. V is seeking stockholder approval to extend the deadline for completing a business combination to November 16, 2025, to finalize its merger with CUBEBIO Co., Ltd.

Summary

• Mountain Crest Acquisition Corp. V is holding an Annual Meeting of Stockholders on November 8, 2024, to vote on several proposals.
• The primary proposal is to amend the company's charter to extend the deadline for completing a business combination from November 16, 2024, to November 16, 2025.
• This extension is sought to allow the company more time to finalize its business combination with CUBEBIO Co., Ltd.
• Stockholders can elect to redeem their shares for approximately $11.55 per share from the Trust Account, regardless of their vote on the extension.
• The company's sponsor, officers, and directors hold a significant number of shares and have interests that may differ from those of public stockholders.
• Failure to approve the extension could lead to the company's liquidation.
• The company is also seeking to elect Nelson Haight as Class II director, ratify the appointment of UHY LLP as auditor, and authorize adjournment of the meeting if necessary.
• The company faces potential delisting from Nasdaq if it cannot complete a business combination by November 12, 2024, which could have adverse consequences.
• As of October 10, 2024, the Trust Account held approximately $6.0 million in marketable securities.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is pursuing a business combination, the need for an extension, potential delisting, and differing interests of the sponsor create uncertainty.

Positives

• Stockholders have the option to redeem their shares for cash at approximately $11.55 per share.
• The company is actively working towards completing a business combination with CUBEBIO.
• The board recommends voting for the extension amendment, indicating their belief in the potential for a successful business combination.
• The company has secured a business combination agreement with CUBEBIO.

Negatives

• Failure to approve the extension will lead to the company's liquidation and the loss of potential gains from a business combination.
• The company faces potential delisting from Nasdaq, which could negatively impact the stock's liquidity and attractiveness.
• The sponsor, officers, and directors have interests that may not align with those of public stockholders.
• Redemptions by public stockholders will decrease the amount in the Trust Account.

Risks

• The company may not be able to complete the business combination with CUBEBIO even if the extension is approved.
• Delisting from Nasdaq could lead to reduced liquidity, penny stock status, and difficulty in raising future capital.
• The company's securities could be subject to increased regulation if delisted from Nasdaq.
• The business combination may be subject to U.S. foreign investment regulations and review by CFIUS, potentially delaying or blocking the transaction.
• The company may be subject to an excise tax on redemptions of common stock.
• If the company is deemed an investment company, it would be required to institute burdensome compliance requirements and its activities would be severely restricted, and, as a result, it may abandon its efforts to consummate the Initial Business Combination and liquidate the Company.

Future Outlook

The company is working towards completing the Business Combination with CUBEBIO and believes it can close the Business Combination before November 16, 2025.

Management Comments

• The Company's management believes that it cannot close the Business Combination before November 16, 2024.
• The Company's management believes that it can close the Business Combination before November 16, 2025.

Industry Context

This announcement is typical for SPACs approaching their business combination deadline, where extensions are often sought to finalize deals.

Comparison to Industry Standards

• Many SPACs seek extensions to complete business combinations, especially in challenging market conditions.
• The redemption price of approximately $11.55 per share is within the typical range for SPACs with assets in trust.
• The potential delisting from Nasdaq is a common risk for SPACs that fail to meet listing requirements or complete a business combination within the allotted time.

Related Party Transactions

• The Sponsor has made an interest-free loan in the aggregate amount of $542,000 to the Company.
• The Company pays the Sponsor, affiliates, or advisors a total of up to $10,000 per month for office space, utilities, out of pocket expenses, and secretarial and administrative support.

Stakeholder Impact

• Stockholders can choose to redeem their shares, potentially impacting the Trust Account balance.
• Employees of the target company (CUBEBIO) may be affected by the outcome of the business combination.
• The company's liquidation would negatively impact stockholders who do not redeem their shares.

Next Steps

• Stockholders will vote on the extension amendment and other proposals at the Annual Meeting on November 8, 2024.
• The company will file the Extension Amendment with the Secretary of State of the State of Delaware if the Extension Amendment Proposal is approved.
• The company will continue to work to consummate a Business Combination by the Extended Date.

Key Dates

Keywords

business combination, extension amendment, CUBEBIO, SPAC, redemption, liquidation, Nasdaq, proxy statement, stockholders, trust account